As of April 30, 2026, LIR Life Sciences Corp. carries a market capitalization of 10.21M, placing it among publicly traded companies globally. Its enterprise value stands at 9.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.21M |
| Enterprise Value | 9.83M |
As of April 30, 2026, LIR Life Sciences Corp. has 28.67M shares outstanding.
| Shares Outstanding | 28.67M |
These figures are as of April 30, 2026.
| PB Ratio | 24.79 |
| P/TBV Ratio | 24.79 |
| P/FCF Ratio | -7.40 |
| P/OCF Ratio | -7.78 |
As of April 30, 2026, LIR Life Sciences Corp. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.64 |
| Quick Ratio | 3.68 |
| Interest Coverage | -5,652.31 |
These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -786.68, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -786.68 |
As of the close on October 22, 2026, LIR Life Sciences Corp.'s stock has declined approximately 43.19% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.38.
| 52-Week Price Change | -43.19% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.38 |
Over the twelve months ended April 30, 2026, LIR Life Sciences Corp. generated - - in revenue and converted that into -2.36M in net income, yielding earnings per share of -0.08. EBITDA reached -2.13M, while operating income came in at -2.09M.
| Operating Income | -2.09M |
| Pretax Income | -2.36M |
| Net Income | -2.36M |
| EBITDA | -2.13M |
| EBIT | -2.13M |
| Earnings Per Share (EPS) | -0.08 |
These figures are as of April 30, 2026. Total book value stands at 411,667.76, with working capital of 411,667.76 providing operational flexibility.
| Cash & Cash Equivalents | 374,204.25 |
| Net Debt | -374,204.25 |
| Equity (Book Value) | 411,667.76 |
| Book Value Per Share | 0.01 |
| Working Capital | 411,667.76 |
LIR Life Sciences Corp. produced -1.28M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -65,856.41 in capital expenditures, free cash flow totaled -1.35M - equivalent to -0.05 per share.
| Operating Cash Flow | -1.28M |
| Capital Expenditures | -65,856.41 |
| Free Cash Flow | -1.35M |
| FCF Per Share | -0.05 |
These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -13.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -13.51 |
LIR Life Sciences Corp.'s most recent stock split took place on November 7, 2025 with a 3:2 split ratio.
| Last Split Date | 11/7/2025 |
| Split Ratio | 3:2 |
As of April 30, 2026, LIR Life Sciences Corp. has an Altman Z-Score of 34.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 34.64 |
Already premium?